Follicular Lymphoma Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Incyte, Genmab, BeiGene, Merck, ADC Therapeutics, MEI Pharma, Xynomic Pharmaceuticals, Nordic Nanovector

Follicular Lymphoma Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Incyte, Genmab, BeiGene, Merck, ADC Therapeutics, MEI Pharma, Xynomic Pharmaceuticals, Nordic Nanovector
Delveinsight Business Research LLP
As per DelveInsight, the Follicular Lymphoma Market is anticipated to evolve immensely in the coming years owing to the rise in the number of cases of Follicular Lymphoma and the launch of new therapies in the market.

DelveInsight’s “Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Follicular Lymphoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Follicular Lymphoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Follicular Lymphoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Follicular Lymphoma: An Overview

As per the Leukemia & Lymphoma Society, Non-Hodgkin Lymphoma (NHL) is a type of cancer that generally develops in the lymph nodes and lymphatic tissue found in organs such as the stomach, intestines, or skin. In some cases, the NHL involves bone marrow and blood. NHL is classified based on the type of lymphocyte involved: B lymphocytes (B cells), T lymphocytes (T-cells), and Natural killer cells. NHL can also be indolent (slow progression) or aggressive (rapid progression).

According to Lymphoma Research Foundation, Follicular Lymphoma is a slow-growing or indolent form of non-Hodgkin lymphoma (NHL) that arises from B-lymphocytes. This lymphoma subtype accounts for 20–30% of all NHL cases. Follicular lymphoma is usually a slow-growing (indolent) lymphoma, although some follicular lymphoma can grow rapidly.

Often patients at the time of diagnosis have obvious symptoms of the disease. The common symptoms of follicular lymphoma include enlargement of the lymph nodes in the neck, underarms, abdomen, or groin, as well as fatigue, shortness of breath, night sweats, and weight loss. If follicular lymphoma occurs in the bone marrow, it leads to anemia, thrombocytopenia, and neutropenia.

Follicular lymphoma is usually diagnosed in higher stages. The stages are divided based on the number of lymph nodes involved. Stage I: one lymph node (or lymph structure) involved; stage II: Two or more lymph nodes (or lymph structures) are involved but only on one side (above or below) of the diaphragm; stage III: lymph nodes (or structures) on both sides of the diaphragm are involved; stage IV: the lymphoma is present in the bone marrow and/or tissues or organs other than lymph nodes or lymph structures.

The treatment of follicular lymphoma is based on the severity of associated symptoms and the rate of cancer growth.

Follicular Lymphoma Market Key Facts

  • The Follicular Lymphoma market size in the seven major markets was USD 1,451 million in 2020.

  • The incident population of Follicular Lymphoma in the 7MM countries was estimated to be 35,737 cases in 2020.

  • A study conducted by Mozas et al. (2020), shows that 54% of follicular lymphoma patients were refractory or experienced relapse/progression during follow-up.

  • As per the study conducted by Smith et al. (2015), titled “Lymphoma incidence, survival and prevalence 2004–2014: subtype analyses from the UK’s Hematological Malignancy Research Network,” the incidence of follicular lymphoma was 3.23/100,000.

  • As per the study by Fujishima et al. (2018), the incidence of follicular lymphoma in Japan was 2.80 per 100,000 persons.

Follicular Lymphoma Market Growth Factors and Associated Trends

The Follicular Lymphoma market exhibits several drivers and barriers that significantly influence its growth trajectory. Drivers encompass various factors propelling market expansion, including advancements in treatment options, particularly immunotherapies and targeted therapies, which have revolutionized Follicular Lymphoma management. Additionally, the rising prevalence of Follicular Lymphoma worldwide and the increasing elderly population contribute to market growth, as this disease primarily affects older individuals. Moreover, heightened research and development initiatives and increased investments in innovative therapies further propel market progression.

However, the Follicular Lymphoma market faces several barriers that hinder its growth potential. One major challenge lies in the high cost of novel therapies, limiting accessibility for a broader patient population. Regulatory complexities and stringent approval processes also pose obstacles to the swift introduction of innovative treatments into the market. Additionally, the complexity of Follicular Lymphoma itself, characterized by diverse genetic mutations and variations in disease progression, presents challenges in developing universally effective therapies. 

Furthermore, the lack of awareness about Follicular Lymphoma among both healthcare providers and patients, leading to delayed diagnosis and treatment initiation, remains a barrier to optimizing disease management. Overcoming these barriers requires collaborative efforts among stakeholders to address cost concerns, streamline regulatory processes, advance research, and enhance awareness to ultimately improve outcomes for Follicular Lymphoma patients.

Follicular Lymphoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Follicular Lymphoma pipeline therapies. It also thoroughly assesses the Follicular Lymphoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Follicular Lymphoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Follicular Lymphoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Follicular Lymphoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Follicular Lymphoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Follicular Lymphoma Epidemiology, Segmented as –

  • Total Follicular Lymphoma Incident Cases

  • Follicular Lymphoma Risk-specific Incident Cases

  • Follicular Lymphoma Stage-specific Incident Cases

  • Follicular Lymphoma Mutation-specific Incident Cases

  • Follicular Lymphoma Refractory/Relapsed Incident Cases

  • Follicular Lymphoma Treatable Cases

Follicular Lymphoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Follicular Lymphoma market or expected to be launched during the study period. The analysis covers the Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Follicular Lymphoma drugs based on their sale and market share.

The report also covers the Follicular Lymphoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Follicular Lymphoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Follicular Lymphoma Market Will Evolve and Grow by 2032 @

Follicular Lymphoma Therapeutics Analysis

There are various treatment options for follicular lymphoma based on the severity of associated symptoms and the rate of cancer growth. If patients show no or very few symptoms, physicians recommend not to treat the disease right away—an approach referred to as active surveillance (“watch and wait”). The treatment of follicular lymphoma includes CAR T cell therapies, chemotherapy, radiation therapy, immunotherapy, and stem cell transplant. Patients with early-stage follicular lymphoma (Ann Arbor stages I or II) may be treated with radiation therapy alone or with radiation plus chemotherapy.

Patients with advanced disease are usually treated first with chemotherapy plus anti-CD20 antibodies, sometimes called chemoimmunotherapy. The most common antibodies used are RITUXAN (rituximab) and GAZYVA (obinutuzumab), which selectively target follicular lymphoma tumor cells. Older people without organ dysfunction can be treated with rituximab only.

In June 2020, the US FDA approved TAZVERIK (tazemetostat) for adult patients with R/R follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by the EZH2 Mutation Test; and for adult patients with R/R follicular lymphoma who have received at least two prior systemic therapies and have no satisfactory alternative treatment options.

In December 2022, the US FDA granted accelerated approval to Genentech’s LUNSUMIO (mosunetuzumab-axgb), a bispecific CD20-directed CD3 T-cell engager for adult patients with R/R follicular lymphoma after two or more lines of systemic therapy.

In November 2023, BeiGene received European Commission approval for BRUKINSA (zanubrutinib) for the treatment of R/R follicular lymphoma BRUKINSA is the first and only BTK inhibitor approved for follicular lymphoma in the European Union.

To improve the treatment scenario, Several major pharma and biotech companies are developing therapies for Follicular Lymphoma. Currently, Genmab is leading the therapeutics market with its Follicular Lymphoma drug candidates in the most advanced stage of clinical development.

Follicular Lymphoma Therapeutic Advancements and Emerging Treatments:

  • Follicular Lymphoma Clinical Trial Progression and Key Companies: The market is set to experience significant growth, driven by the progression of emerging therapies expected for launch between 2023 and 2032. Pioneering companies, including Incyte Corporation, Genmab A/S, BeiGene, Merck & Co., ADC Therapeutics, Xynomic Pharmaceuticals, Nordic Nanovector, TG Therapeutics Inc., Allogene Therapeutics, MEI Pharma, Innovent Biologics, and others, are actively engaged in developing novel drugs for potential market entry.

  • Follicular Lymphoma Emerging and Marketed Therapies: Ongoing research and development activities are fostering the introduction of innovative therapies designed to address the signs and symptoms of Follicular Lymphoma. Some of the emerging therapies in the pipeline include Tafasitamab (Incyte Corporation), Epcoritamab (Genmab A/S), Zanubrutinib (BeiGene), Pembrolizumab (Merck & Co.), and others.

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Follicular Lymphoma Competitive Intelligence Analysis

4. Follicular Lymphoma Market Overview at a Glance

5. Follicular Lymphoma Disease Background and Overview

6. Follicular Lymphoma Patient Journey

7. Follicular Lymphoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Follicular Lymphoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Follicular Lymphoma Unmet Needs

10. Key Endpoints of Follicular Lymphoma Treatment

11. Follicular Lymphoma Marketed Therapies

12. Follicular Lymphoma Emerging Drugs and Latest Therapeutic Advances

13. Follicular Lymphoma Seven Major Market Analysis

14. Attribute Analysis

15. Follicular Lymphoma Market Outlook (In US, EU5, and Japan)

16. Follicular Lymphoma Companies Active in the Market

17. Follicular Lymphoma Access and Reimbursement Overview

18. KOL Views on the Follicular Lymphoma Market

19. Follicular Lymphoma Market Drivers

20. Follicular Lymphoma Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Amyloidosis Market

“Amyloidosis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Amyloidosis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Amyloidosis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States